Equillium Announces Data From Phase 1b EQUALISE Study Was Presented At 2023 Annual Meeting Of The American Society Of Nephrology
Portfolio Pulse from Benzinga Newsdesk
Equillium has presented data from its Phase 1b EQUALISE study at the 2023 Annual Meeting of the American Society of Nephrology. The study shows that Itolizumab continues to demonstrate a clinically meaningful response in highly proteinuric subjects. At Week 28, 73% of subjects achieved more than 50% reduction in urine protein creatinine ratio (UPCR). Itolizumab also showed a favorable safety and tolerability profile.
November 06, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Equillium's Phase 1b EQUALISE study shows promising results for Itolizumab, which could potentially lead to increased investor interest and a positive impact on the company's stock.
Positive clinical trial results often lead to increased investor interest as they indicate potential future revenue from the product under study. In this case, the positive results from Equillium's Phase 1b EQUALISE study for Itolizumab could lead to increased investor interest in the company, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100